Cactus Life Sciences
24.4.2024 15:48:41 CEST | ACCESS Newswire | Press release
Cactus Life Sciences has begun their exciting buy-and-build strategy adding key services to their portfolio
PRINCETON, NJ / ACCESSWIRE / April 24, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that they have acquired nspm and eluSCIdate, two dynamic medical communications and publications companies headquartered in Meggen, Switzerland with an office in the UK.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.logo lockup
Cactus Life Sciences, headquartered in Princeton, New Jersey, was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. Founded 27 years ago, nspm brings extensive expertise in medical communications, publications, and event management, with a focus on rare diseases. Its sister company eluSCIdate was founded in 2020 and focuses on medical and scientific publications, combining extensive experience in medical writing with creative flair to deliver high-quality publications.
This collaboration signifies a major step forward in enhancing services for our biopharma clients, ensuring a comprehensive and fully integrated global approach to medical communications. And provides a significant employee footprint in US, UK, Switzerland, and Japan.
"As Cactus Life Sciences embarks on its forthcoming buy-and-build strategy, we're excited to unveil our first acquisition that shares so many of the same values as CACTUS, stated Oliver Dennis, the new Chairman of Cactus Life Sciences. "As we move forward, we seek partnerships that prioritize our people and clients alongside our strategic growth."
Rare diseases individually affect a small number of people, but collectively affect over 300 million worldwide, presenting significant challenges for patients and medical professionals. nspm's rare disease expertise addresses unmet needs for patients and society. Sabine Stotz, PhD, Managing Director, nspm, noted "This strategic alliance is a testament to the shared vision of excellence between Cactus Life Sciences, nspm and eluSCIdate. Together, our goal is to enrich the global landscape of scientific communications creating an even greater impact on healthcare professionals and the patients they treat".
Elvira Dsouza, President, Cactus Life Sciences remarked, "Cactus Life Sciences stands out for its unwavering commitment to excellence, innovation, and future readiness. With a focus on integrating cutting-edge technology, notably AI, we aim to elevate scientific content creation to contribute to a more accessible, informed, and transformative healthcare landscape".
About Cactus Life Sciences (cactuslifesciences.com): Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world ─ with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes.
About nspm (www.nspm.com): nspm is a successful and dynamic medical communications company founded in 1997 with offices in Switzerland and the UK. nspm provides a complete range of medical writing, project management, and strategic medical communications solutions for the pharmaceutical and biotech industry across a range of therapeutic areas, with a focus on rare diseases. Our employees are committed to crafting high-quality, cost-effective solutions that exceed clients' expectations through scientific excellence, professionalism, and creativity.
About eluSCIdate (www.eluscidate.com): eluSCIdate is a medical writing agency founded in 2020 that specializes in scientific publications, providing support for the entire publication process. We use a wealth of experience in medical writing to deliver high-quality manuscripts, posters, and slides to our clients. At eluSCIdate, we are passionate about science and committed to providing clarity in scientific messaging. Through effective communication, we work with our clients to ensure their science stands out from the crowd.
Contact Information:
Laura Perry
VP of Strategy and Marketing
inquiries@cactuslifesciences.com
7327121005
SOURCE: Cactus Life Sciences
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
